FDA
-
-
-
-
-
-
-
Axsome Therapeutics to Participate in Upcoming Investor Conferences
-
-
-
-
-
-
-
Axsome AUVELITY wins FDA approval for Alzheimer's agitation treatment
-
-
-
-
-
-
-
Oppenheimer on Axsome Therapeutics (AXSM): balipodect acquisition bolsters late-stage pipeline
-
-
-
-
-
-
-
Axsome Therapeutics (AXSM) PT Raised to $215 at TD Cowen
-
-
-
-
-
-
-
Axsome Therapeutics reports preliminary 2025 revenue of $638.5 million
-
-
-
-
-
-
-
Axsome Therapeutics (AXSM) PT Raised to $217 at Mizuho
-
-
-
-
-
-
-
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA Submission
-
322,517 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

